Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/22714

Title: Antibody profiling identifies novel antigenic targets in spinal cord injury patients
Authors: Palmers, Ilse
Ydens, Elke
Put, Eric
Depreitere, Bart
Bongers-Janssen, Helma
Pickkers, Peter
Hendrix, Sven
Somers, Veerle
Issue Date: 2016
Citation: JOURNAL OF NEUROINFLAMMATION, 13, p. 1-11 (Art N° 243)
Abstract: Background: Recent evidence implicates antibody responses as pivotal damaging factors in spinal cord injury (SCI)-induced neuroinflammation. To date, only a limited number of the antibody targets have been uncovered, and the discovery of novel targets with pathologic and clinical relevance still represents a major challenge. Methods: In this study, we, therefore, applied an unbiased, innovative and powerful strategy, called serological antigen selection (SAS), to fully identify the complex information present within the antibody repertoire of SCI patients. Results: We constructed a high-quality cDNA phage display library derived from human spinal cord tissue to screen for antibody reactivity in pooled plasma samples from traumatic SCI patients (n = 10, identification cohort). By performing SAS, we identified a panel of 19 antigenic targets to which the individual samples of the plasma pool showed antibody reactivity. Sequence analysis to identify the selected antigenic targets uncovered 5 known proteins, to which antibody reactivity has not been associated with SCI before, as well as linear peptides. Immunoreactivity against 9 of the 19 novel identified targets was validated in 41 additional SCI patients and an equal number of age-and gender-matched healthy subjects. Overall, we found elevated antibody levels to at least 1 of the 9 targets in 51 % of our total SCI patient cohort (n = 51) with a specificity of 73 %. By combining 6 of these 9 targets into a panel, an overall reactivity of approximately half of the SCI patients could be maintained while increasing the specificity to 82 %. Conclusions: In conclusion, our innovative high-throughput approach resulted in the identification of previously unexplored antigenic targets with elevated immunoreactivity in more than 50 % of the SCI patients. Characterization of the validated antibody responses and their targets will not only provide new insight into the underlying disease processes of SCI pathology but also significantly contribute to uncovering potential antibody biomarkers for SCI patients.
Notes: [Palmers, Ilse; Ydens, Elke; Hendrix, Sven; Somers, Veerle] Hasselt Univ, Biomed Res Inst, Martelarenlaan 42, Hasselt, Belgium. [Palmers, Ilse; Ydens, Elke; Hendrix, Sven; Somers, Veerle] Hasselt Univ, Sch Life Sci, Transnat Univ Limburg, Martelarenlaan 42, Hasselt, Belgium. [Put, Eric] Jessa Hosp, Dept Neurosurg, Stadsomvaart 11, Hasselt, Belgium. [Depreitere, Bart] Katholieke Univ Leuven, Div Expt Neurosurg & Neuroanat, Herestr 49, Leuven, Belgium. [Depreitere, Bart] Univ Hosp Leuven, Herestr 49, Leuven, Belgium. [Bongers-Janssen, Helma] Adelante Rehabil, Zandbergsweg 111, Hoensbroek, Netherlands. [Pickkers, Peter] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Intens Care Med, Geert Grootepl Zuid 10, Nijmegen, Netherlands.
URI: http://hdl.handle.net/1942/22714
DOI: 10.1186/s12974-016-0713-5
ISI #: 000384618300001
ISSN: 1742-2094
Category: A1
Type: Journal Contribution
Validation: ecoom, 2017
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version784.7 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.